JP2015517496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517496A5 JP2015517496A5 JP2015511575A JP2015511575A JP2015517496A5 JP 2015517496 A5 JP2015517496 A5 JP 2015517496A5 JP 2015511575 A JP2015511575 A JP 2015511575A JP 2015511575 A JP2015511575 A JP 2015511575A JP 2015517496 A5 JP2015517496 A5 JP 2015517496A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- set forth
- domain
- pnag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007943 implant Substances 0.000 claims 8
- 241000295644 Staphylococcaceae Species 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000000813 microbial effect Effects 0.000 claims 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 206010011409 Cross infection Diseases 0.000 claims 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 206010060968 Arthritis infective Diseases 0.000 claims 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 1
- 206010029803 Nosocomial infection Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010062255 Soft tissue infection Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643650P | 2012-05-07 | 2012-05-07 | |
| US61/643,650 | 2012-05-07 | ||
| FR1352399 | 2013-03-18 | ||
| FR1352399 | 2013-03-18 | ||
| PCT/US2013/039724 WO2013169657A1 (en) | 2012-05-07 | 2013-05-06 | Methods for preventing biofilm formation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517496A JP2015517496A (ja) | 2015-06-22 |
| JP2015517496A5 true JP2015517496A5 (enExample) | 2016-06-23 |
Family
ID=52691156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511575A Pending JP2015517496A (ja) | 2012-05-07 | 2013-05-06 | バイオフィルム形成を防止する方法 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20150086601A1 (enExample) |
| JP (1) | JP2015517496A (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020518251A (ja) * | 2017-05-04 | 2020-06-25 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 抗体可変ドメイン及び抗体構築物 |
| BR112022009924A2 (pt) * | 2019-11-22 | 2022-08-09 | Alopexx Inc | Métodos para fornecer terapia contínua contra pnag compreendendo micróbios |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2567748A1 (en) * | 2004-04-21 | 2005-11-03 | The Brigham And Women's Hospital, Inc. | Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof |
-
2013
- 2013-05-06 US US14/396,897 patent/US20150086601A1/en not_active Abandoned
- 2013-05-06 JP JP2015511575A patent/JP2015517496A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518599A5 (enExample) | ||
| JP2017524344A5 (enExample) | ||
| WO2009043476A3 (en) | Neuromedin s as a therapeutic agent | |
| JP2015529225A5 (enExample) | ||
| JP2014169326A5 (enExample) | ||
| JP2016501892A5 (enExample) | ||
| WO2008144130A3 (en) | Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties | |
| WO2009046824A3 (en) | Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis | |
| JP2016527217A5 (enExample) | ||
| NZ596807A (en) | Uses of immunoconjugates targeting cd138 | |
| WO2009039983A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033789A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009040031A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2008039722A3 (en) | External catheter with antiseptic agent | |
| WO2009043436A3 (en) | Use of af12198 as a therapeutic agent | |
| NZ596274A (en) | Blocking anti-dkk-1 antibodies and their uses | |
| BR112013028914A2 (pt) | antagonistas de receptores de integrina e seus métodos de uso | |
| WO2009033730A3 (en) | Peptide gxgrgdspca as a therapeutic agent | |
| WO2009040048A3 (en) | Use of the c-reactive peptide as a therapeutic agent | |
| WO2009033757A3 (en) | Use of mage-3 antigen (271-279) as a therapeutic agent | |
| WO2009040072A3 (en) | Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis | |
| WO2009046829A3 (en) | Casoxin d as a therapeutic agent | |
| WO2009040035A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009043447A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2011113507A3 (en) | Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns |